The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).
 
Andrew W Hahn
No Relationships to Disclose
 
Omar Alhalabi
No Relationships to Disclose
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Alphasights; Axiom Biotechnologies; Bayer; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Trieza Therapeutics; WebMD
Research Funding - Abbvie; Adaptimmune; Aldai Norte; Amgen; AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Fate Therapeutics; Genentech; Infinity Pharmaceuticals; Kite, a Gilead company; Kura Oncology; MedImmune; Mirati Therapeutics; Molecular Templates; National Cancer Institute; Pfizer; Seagen; Shattuck Labs; TCR2 Therapeutics; TP Therapeutics
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - TYME; Xencor
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen; Ipsen; Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Timothy A Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - Atrin Pharmaceuticals; Calithera Biosciences; EMD Serono; Leidos Biomedical Research; Lilly; Pfizer; Tesaro
 
Erick Campbell
No Relationships to Disclose
 
Hung Le
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology
 
Jason Roszik
No Relationships to Disclose
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape